article Open AccessTop 1% cited

Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure

New England Journal of Medicine · 2005 · Vol. 352(3) · pp. 225–237

Gust H. Bardy✉(The Seattle Institute for Cardiac Research)Kerry L. Lee(Duke University)Daniel B. Mark(Duke University)Jeanne E. Poole(University of Washington)Douglas L. Packer(Mayo Clinic in Arizona)Robin Boineau(National Heart Lung and Blood Institute)Michaël Domanski(National Heart Lung and Blood Institute)Charles Troutman(The Seattle Institute for Cardiac Research)Jill Anderson(The Seattle Institute for Cardiac Research)George Johnson(The Seattle Institute for Cardiac Research)Steven E. McNulty(Duke University)Nancy E. Clapp‐Channing(Duke University)Linda Davidson‐Ray(Duke University)Elizabeth Fraulo(Duke University)Daniel P. Fishbein(University of Washington)Richard M. LuceriJames E. Ip

View via DOI Full-text PDF

Abstract

In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.

Cardiac pacing and defibrillation studies Cardiac electrophysiology and arrhythmias Cardiac Arrhythmias and TreatmentsMedicineAmiodaroneEjection fractionHazard ratioHeart failureCardiologyInternal medicinePlaceboImplantable cardioverter-defibrillatorSudden death

MeSH terms

AgedAmiodaroneAnti-Arrhythmia AgentsCause of DeathFemaleHeart FailureHumansMaleMiddle AgedRiskStroke VolumeSurvival AnalysisDeath, Sudden, CardiacDefibrillators, ImplantableCross-Over Studies

Citations

6,492

FWCI

260.32

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary